NFKB1 and cancer: The co-administration of Irinotecan and GRA16 promoted the anti-cancer effects of Irinotecan by inhibiting NF-κB and cell cycle arrest induced by GRA16, ultimately increasing the effectiveness of Irinotecan in treating non-small-cell lung carcinoma [176].